CA3174484A1 - Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer - Google Patents
Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transferInfo
- Publication number
- CA3174484A1 CA3174484A1 CA3174484A CA3174484A CA3174484A1 CA 3174484 A1 CA3174484 A1 CA 3174484A1 CA 3174484 A CA3174484 A CA 3174484A CA 3174484 A CA3174484 A CA 3174484A CA 3174484 A1 CA3174484 A1 CA 3174484A1
- Authority
- CA
- Canada
- Prior art keywords
- bioactive agent
- bret
- binding
- nanoluc
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012867 bioactive agent Substances 0.000 title claims abstract description 167
- 230000001413 cellular effect Effects 0.000 title claims abstract description 139
- 230000027455 binding Effects 0.000 title claims abstract description 111
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 title claims description 144
- 230000003834 intracellular effect Effects 0.000 title abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 230000004927 fusion Effects 0.000 claims description 55
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 239000000758 substrate Substances 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 34
- 150000003384 small molecules Chemical class 0.000 claims description 33
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical group C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 claims description 24
- 108060001084 Luciferase Proteins 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000005089 Luciferase Substances 0.000 claims description 16
- -1 carboxy rhodamine analog Chemical class 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 238000000295 emission spectrum Methods 0.000 claims description 8
- 230000005284 excitation Effects 0.000 claims description 5
- 230000008823 permeabilization Effects 0.000 claims description 4
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 238000000695 excitation spectrum Methods 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- 230000003993 interaction Effects 0.000 abstract description 106
- 238000001514 detection method Methods 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 11
- 238000004458 analytical method Methods 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 164
- 101100443626 Mus musculus Dner gene Proteins 0.000 description 141
- 108700043045 nanoluc Proteins 0.000 description 70
- 229940079593 drug Drugs 0.000 description 55
- 239000003814 drug Substances 0.000 description 55
- 230000000295 complement effect Effects 0.000 description 48
- 239000000700 radioactive tracer Substances 0.000 description 47
- 150000001875 compounds Chemical class 0.000 description 37
- 238000012546 transfer Methods 0.000 description 32
- 238000006073 displacement reaction Methods 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 29
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 28
- 229960000237 vorinostat Drugs 0.000 description 28
- HTBLMRUZSCCOLL-UHFFFAOYSA-N 8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3-ol Chemical compound OC1=C(CC2=CC=CO2)N=C2N1C=C(N=C2CC1=CC=CC=C1)C1=CC=CC=C1 HTBLMRUZSCCOLL-UHFFFAOYSA-N 0.000 description 27
- 238000001890 transfection Methods 0.000 description 26
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 24
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 230000002860 competitive effect Effects 0.000 description 23
- 239000000975 dye Substances 0.000 description 23
- 239000000370 acceptor Substances 0.000 description 21
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 108091005625 BRD4 Proteins 0.000 description 19
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 18
- 108020001507 fusion proteins Proteins 0.000 description 18
- 239000003446 ligand Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 238000005259 measurement Methods 0.000 description 16
- 102000003964 Histone deacetylase Human genes 0.000 description 14
- 108090000353 Histone deacetylase Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000003595 spectral effect Effects 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000012124 Opti-MEM Substances 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000004020 luminiscence type Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000012679 serum free medium Substances 0.000 description 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 230000036515 potency Effects 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108010085220 Multiprotein Complexes Proteins 0.000 description 7
- 102000007474 Multiprotein Complexes Human genes 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 6
- 101150031398 MAPK9 gene Proteins 0.000 description 6
- 239000003596 drug target Substances 0.000 description 6
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 6
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 6
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 6
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 108700012928 MAPK14 Proteins 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 4
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 4
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 4
- 108010047357 Luminescent Proteins Proteins 0.000 description 4
- 102000006830 Luminescent Proteins Human genes 0.000 description 4
- 101150003941 Mapk14 gene Proteins 0.000 description 4
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 4
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 4
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 4
- 241000242739 Renilla Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- JIAUJOOGSKJAFH-UHFFFAOYSA-N coelenteramide Chemical compound C1=CC(O)=CC=C1CC(=O)NC(N=CC(N1)=C2C=CC(=O)C=C2)=C1CC1=CC=CC=C1 JIAUJOOGSKJAFH-UHFFFAOYSA-N 0.000 description 4
- 229960002448 dasatinib Drugs 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 229940082789 erbitux Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229960001972 panitumumab Drugs 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 3
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 description 3
- 241001443978 Oplophorus Species 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- CJIIERPDFZUYPI-UHFFFAOYSA-N coelenteramide Natural products C1=CC(O)=CC=C1CC(=O)NC1=NC=C(C=2C=CC(O)=CC=2)N=C1CC1=CC=CC=C1 CJIIERPDFZUYPI-UHFFFAOYSA-N 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 3
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000009120 phenotypic response Effects 0.000 description 3
- 238000003498 protein array Methods 0.000 description 3
- 230000012743 protein tagging Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical class [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 2
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 101710107444 Polyamine deacetylase HDAC10 Proteins 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000008606 intracellular interaction Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229940100684 pentylamine Drugs 0.000 description 2
- 238000012247 phenotypical assay Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZKDXRFMOHZVXSG-HNNXBMFYSA-N purvalanol B Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=C(C(O)=O)C(Cl)=C1 ZKDXRFMOHZVXSG-HNNXBMFYSA-N 0.000 description 2
- 238000002165 resonance energy transfer Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- QHFKWIKCUHNXAU-UHFFFAOYSA-N (4-nitrophenyl) carbamate Chemical compound NC(=O)OC1=CC=C([N+]([O-])=O)C=C1 QHFKWIKCUHNXAU-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MPPQGYCZBNURDG-UHFFFAOYSA-N 2-propionyl-6-dimethylaminonaphthalene Chemical compound C1=C(N(C)C)C=CC2=CC(C(=O)CC)=CC=C21 MPPQGYCZBNURDG-UHFFFAOYSA-N 0.000 description 1
- BNBQQYFXBLBYJK-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-oxazole Chemical compound C1=COC(C=2N=CC=CC=2)=N1 BNBQQYFXBLBYJK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UWAUSMGZOHPBJJ-UHFFFAOYSA-N 4-nitro-1,2,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=C1N=NO2 UWAUSMGZOHPBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- 102000010084 Group III Histone Deacetylases Human genes 0.000 description 1
- 108010077337 Group III Histone Deacetylases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001115390 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 5 Proteins 0.000 description 1
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101150113474 MAPK10 gene Proteins 0.000 description 1
- 108700027654 Mitogen-Activated Protein Kinase 10 Proteins 0.000 description 1
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 description 1
- 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 description 1
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001505950 Photuris pensylvanica Species 0.000 description 1
- 108010010522 Phycobilisomes Proteins 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 241000238584 Vargula Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 101150036617 fu gene Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- GHTWDWCFRFTBRB-UHFFFAOYSA-M oxazine-170 Chemical compound [O-]Cl(=O)(=O)=O.N1=C2C3=CC=CC=C3C(NCC)=CC2=[O+]C2=C1C=C(C)C(N(C)CC)=C2 GHTWDWCFRFTBRB-UHFFFAOYSA-M 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 210000002306 phycobilisome Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736429P | 2012-12-12 | 2012-12-12 | |
| US61/736,429 | 2012-12-12 | ||
| US201361794461P | 2013-03-15 | 2013-03-15 | |
| US61/794,461 | 2013-03-15 | ||
| US201361880048P | 2013-09-19 | 2013-09-19 | |
| US61/880,048 | 2013-09-19 | ||
| CA2894435A CA2894435A1 (en) | 2012-12-12 | 2013-12-12 | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2894435A Division CA2894435A1 (en) | 2012-12-12 | 2013-12-12 | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174484A1 true CA3174484A1 (en) | 2014-06-19 |
Family
ID=50934963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174484A Pending CA3174484A1 (en) | 2012-12-12 | 2013-12-12 | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
| CA2894435A Pending CA2894435A1 (en) | 2012-12-12 | 2013-12-12 | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2894435A Pending CA2894435A1 (en) | 2012-12-12 | 2013-12-12 | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10024862B2 (enExample) |
| EP (2) | EP3712154A1 (enExample) |
| JP (4) | JP6751294B2 (enExample) |
| KR (2) | KR102150479B1 (enExample) |
| CN (2) | CN104871001B (enExample) |
| AU (1) | AU2013359166B2 (enExample) |
| BR (1) | BR112015013710B1 (enExample) |
| CA (2) | CA3174484A1 (enExample) |
| DK (1) | DK2932267T3 (enExample) |
| ES (1) | ES2803503T3 (enExample) |
| PL (1) | PL2932267T3 (enExample) |
| SG (1) | SG11201504525VA (enExample) |
| WO (1) | WO2014093677A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524457B2 (en) | 2009-09-22 | 2013-09-03 | William Patterson | Method for the selection of specific affinity binders by homogeneous noncompetitive assay |
| US10067149B2 (en) | 2012-12-12 | 2018-09-04 | Promega Corporation | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
| US10024862B2 (en) * | 2012-12-12 | 2018-07-17 | Promega Corporation | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
| ES2926463T3 (es) * | 2013-03-15 | 2022-10-26 | Promega Corp | Activación de la bioluminiscencia mediante complementación estructural |
| CN104225611B (zh) * | 2013-06-18 | 2017-06-30 | 天津键凯科技有限公司 | 达沙替尼与非线性构型聚乙二醇的结合物 |
| US11365402B2 (en) | 2014-09-12 | 2022-06-21 | Promega Corporation | Internal protein tags |
| EP3191601B1 (en) * | 2014-09-12 | 2022-11-02 | Promega Corporation | Internal protein tags |
| WO2016127100A1 (en) * | 2015-02-05 | 2016-08-11 | Promega Corporation | Luciferase-based thermal shift assays |
| EP3436037A4 (en) * | 2016-03-31 | 2019-12-04 | University of Southern California | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION |
| WO2017206041A1 (zh) * | 2016-05-31 | 2017-12-07 | 王帅 | 测定细胞内配体靶蛋白相互作用持久力的方法 |
| JP7200102B2 (ja) * | 2016-11-01 | 2023-01-06 | プロメガ コーポレイション | エネルギー受容体に係留されたセレンテラジン類縁体 |
| CN110226087A (zh) * | 2017-01-27 | 2019-09-10 | 国立大学法人大阪大学 | 生物体物质的检测方法、该方法中使用的化学发光指示剂 |
| EP3578978B1 (en) * | 2017-02-03 | 2022-07-13 | Osaka University | Device and determination system using same |
| US11442063B2 (en) | 2018-05-30 | 2022-09-13 | Promega Corporation | Broad spectrum kinase binding agents |
| WO2020041579A1 (en) | 2018-08-23 | 2020-02-27 | Promega Corporation | Coelenterazine analogues |
| WO2020048607A1 (en) | 2018-09-07 | 2020-03-12 | Université Libre de Bruxelles | Srsf2 as rna epigenetic factor |
| JP7703446B2 (ja) | 2018-11-28 | 2025-07-07 | プロメガ コーポレイション | 反応性ペプチド標識付け |
| JP7584433B2 (ja) | 2019-03-20 | 2024-11-15 | プロメガ コーポレイション | 光親和性プローブ |
| EP3953374A4 (en) * | 2019-04-10 | 2023-06-07 | Promega Corporation | COMPOSITIONS AND METHODS FOR DETECTION OF ANALYTES USING BIOLUMINESCENCE |
| CN112147114B (zh) * | 2019-06-27 | 2024-06-25 | 成都先导药物开发股份有限公司 | 一种利用荧光标记化合物确定化合物在活细胞中与靶标相互作用的方法 |
| EP4073512B1 (en) | 2019-12-10 | 2025-11-12 | Promega Corporation | Compositions and methods for bioluminescent detection using multifunctional probes |
| US20220064696A1 (en) * | 2020-08-28 | 2022-03-03 | Promega Corporation | Target engagement assay for ras proteins |
| CN118703457A (zh) * | 2021-04-01 | 2024-09-27 | 深圳华大生命科学研究院 | 一种刺虾荧光素酶Nluc的突变体及其应用 |
| CN114394970B (zh) * | 2022-01-05 | 2023-06-06 | 山东大学 | 一种酯类Furimazine衍生物及制备方法与应用 |
| CN114813706B (zh) * | 2022-06-29 | 2022-12-13 | 国科大杭州高等研究院 | 一种血细胞高光谱光镊捕获能量共振转移分析仪 |
| JP2025536247A (ja) | 2022-10-14 | 2025-11-05 | プロメガ コーポレイション | セレンテラジン類似体 |
| CN116354927B (zh) * | 2023-02-21 | 2025-02-07 | 杭州医学院 | 以烷烃或脂肪酸为连接链的hdac降解剂及其制备方法和应用 |
| US20240368565A1 (en) * | 2023-05-04 | 2024-11-07 | Promega Corporation | Complementation-based tags and reporters for dual-modality labeling |
| KR20250004513A (ko) | 2023-06-29 | 2025-01-08 | 부산대학교 산학협력단 | Bret-기반 rab11a 활성 바이오센서 및 이를 포함하는 세포주 |
| CN117330755B (zh) * | 2023-08-25 | 2024-03-26 | 广东省农业科学院农业生物基因研究中心 | 一种基于酶催化生物荧光定量检测dna-蛋白质相互作用的方法 |
| KR102802452B1 (ko) | 2023-11-07 | 2025-05-08 | 대한민국 | LgBiT 단백질을 발현하는 세포주 및 HiBiT 단백질을 발현하는 구제역 바이러스를 이용한 구제역 바이러스 감염 여부 확인방법 |
| US20250206747A1 (en) | 2023-12-20 | 2025-06-26 | Promega Corporation | Coelenterazine analogues |
| CN119709661B (zh) * | 2024-12-30 | 2025-10-10 | 佰翱得(无锡)新药开发有限公司 | 一种荧光素酶OLuc突变体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5928888A (en) * | 1996-09-26 | 1999-07-27 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities |
| CA2335305C (en) | 1998-06-16 | 2006-05-23 | Biosignal Packard Inc. | A bioluminescence resonance energy transfer (bret) system and its use |
| ATE320000T1 (de) | 1999-12-22 | 2006-03-15 | Perkinelmer Biosignal Inc | Ein biolumineszenz resonanz energie transfer (bret) system mit breitem spektralen resolution zwischen donator- und akzeptor-emission wellenlänge und ihre anwendung |
| WO2002029410A2 (en) | 2000-10-06 | 2002-04-11 | Quantum Dot Corporation | Cells having a spectral signature, and methods of preparation and use thereof |
| DE10058091A1 (de) * | 2000-11-23 | 2002-06-06 | Bayer Ag | Isolierte Luziferasen Lu164, LuAL und Lu22, sowie deren Verwendung |
| US20060099646A1 (en) * | 2002-10-11 | 2006-05-11 | Anders Heding | Bret assay |
| GB0307559D0 (en) | 2003-04-02 | 2003-05-07 | Univ Nottingham | Fluorescently tagged ligands |
| CN100473988C (zh) * | 2004-07-08 | 2009-04-01 | 厦门大学 | 具有荧光共振能量转移特点的蛋白组合及其用途 |
| WO2006086883A1 (en) * | 2005-02-16 | 2006-08-24 | Universite De Montreal | Biosensors for monitoring receptor-mediated g-protein activation |
| GB0625678D0 (en) * | 2006-12-21 | 2007-01-31 | Lux Biotechnology Ltd | Composition and method for detection of demineralisation |
| WO2008109463A2 (en) * | 2007-03-02 | 2008-09-12 | University Of Massachusetts | Red-shifted luciferase |
| EP2006686A1 (en) * | 2007-06-22 | 2008-12-24 | Institut Pasteur | Method for screening for selective modulator of the NF-kB pathway activation |
| EP2215227A2 (en) * | 2007-11-05 | 2010-08-11 | Promega Corporation | Hybrid fusion reporter and uses thereof |
| US8962341B2 (en) * | 2008-12-12 | 2015-02-24 | The Commonwealth Medical College | Cell-based detection of APF through its interaction with CKAP4 for diagnosis of interstitial cystitis |
| KR101665352B1 (ko) | 2009-05-01 | 2016-10-12 | 프로메가 코포레이션 | 광 출력이 향상된 합성 오플로포러스 루시퍼라제 |
| US8263350B2 (en) * | 2009-06-29 | 2012-09-11 | The University Of Chicago | Molecular affinity clamp technology and uses thereof |
| AU2011323418B2 (en) * | 2010-11-02 | 2017-07-27 | Promega Corporation | Novel coelenterazine substrates and methods of use |
| EP2782916B1 (en) * | 2011-11-21 | 2018-02-28 | Promega Corporation | Carboxy x rhodamine analogs |
| CN102798717B (zh) * | 2012-06-15 | 2014-11-26 | 杭州师范大学 | 一种o6-甲基鸟嘌呤-dna甲基转移酶活性检测方法 |
| US10067149B2 (en) | 2012-12-12 | 2018-09-04 | Promega Corporation | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
| US10024862B2 (en) | 2012-12-12 | 2018-07-17 | Promega Corporation | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer |
-
2013
- 2013-12-12 US US14/104,860 patent/US10024862B2/en active Active
- 2013-12-12 ES ES13861977T patent/ES2803503T3/es active Active
- 2013-12-12 CN CN201380064252.4A patent/CN104871001B/zh active Active
- 2013-12-12 CA CA3174484A patent/CA3174484A1/en active Pending
- 2013-12-12 EP EP20169678.8A patent/EP3712154A1/en active Pending
- 2013-12-12 CA CA2894435A patent/CA2894435A1/en active Pending
- 2013-12-12 BR BR112015013710-5A patent/BR112015013710B1/pt active IP Right Grant
- 2013-12-12 JP JP2015547562A patent/JP6751294B2/ja active Active
- 2013-12-12 AU AU2013359166A patent/AU2013359166B2/en active Active
- 2013-12-12 WO PCT/US2013/074765 patent/WO2014093677A1/en not_active Ceased
- 2013-12-12 SG SG11201504525VA patent/SG11201504525VA/en unknown
- 2013-12-12 PL PL13861977T patent/PL2932267T3/pl unknown
- 2013-12-12 KR KR1020157018230A patent/KR102150479B1/ko active Active
- 2013-12-12 EP EP13861977.0A patent/EP2932267B1/en active Active
- 2013-12-12 DK DK13861977.0T patent/DK2932267T3/da active
- 2013-12-12 CN CN201810902469.2A patent/CN109612981B/zh active Active
- 2013-12-12 KR KR1020207024622A patent/KR102292431B1/ko active Active
-
2019
- 2019-01-21 JP JP2019007974A patent/JP7092691B2/ja active Active
-
2022
- 2022-02-14 JP JP2022020320A patent/JP7393451B2/ja active Active
-
2023
- 2023-08-22 JP JP2023134744A patent/JP7676487B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102292431B1 (ko) | 2021-08-20 |
| JP2022078077A (ja) | 2022-05-24 |
| EP2932267A4 (en) | 2016-06-22 |
| ES2803503T3 (es) | 2021-01-27 |
| JP7676487B2 (ja) | 2025-05-14 |
| JP2016500263A (ja) | 2016-01-12 |
| US20140194307A1 (en) | 2014-07-10 |
| EP2932267A1 (en) | 2015-10-21 |
| CN109612981A (zh) | 2019-04-12 |
| BR112015013710B1 (pt) | 2022-08-09 |
| AU2013359166A1 (en) | 2015-07-09 |
| JP7092691B2 (ja) | 2022-06-28 |
| PL2932267T3 (pl) | 2020-10-19 |
| WO2014093677A1 (en) | 2014-06-19 |
| JP6751294B2 (ja) | 2020-09-02 |
| KR20150094696A (ko) | 2015-08-19 |
| JP2023179413A (ja) | 2023-12-19 |
| KR102150479B1 (ko) | 2020-09-01 |
| AU2013359166B2 (en) | 2019-09-19 |
| JP7393451B2 (ja) | 2023-12-06 |
| CN104871001B (zh) | 2018-09-11 |
| BR112015013710A2 (pt) | 2018-11-21 |
| CA2894435A1 (en) | 2014-06-19 |
| JP2019071899A (ja) | 2019-05-16 |
| SG11201504525VA (en) | 2015-07-30 |
| CN104871001A (zh) | 2015-08-26 |
| EP2932267B1 (en) | 2020-05-06 |
| US10024862B2 (en) | 2018-07-17 |
| CN109612981B (zh) | 2022-05-13 |
| KR20200104928A (ko) | 2020-09-04 |
| EP3712154A1 (en) | 2020-09-23 |
| DK2932267T3 (da) | 2020-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7676487B2 (ja) | 細胞内生体発光共鳴エネルギ移動を用いた生物活性剤による細胞ターゲット結合の認知 | |
| US20230417778A1 (en) | Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer | |
| Cheng et al. | Fluorescent amino acids as versatile building blocks for chemical biology | |
| JP7280842B2 (ja) | 構造的相補性による生物発光の活性化 | |
| Böhme et al. | Illuminating the life of GPCRs | |
| AU2010224363B2 (en) | Protein fragment complementation assays for high-throughput and high-content screening | |
| Wolf et al. | Strategies for site‐specific labeling of receptor proteins on the surfaces of living cells by using genetically encoded peptide tags | |
| Chen et al. | Single-chain lanthanide luminescence biosensors for cell-based imaging and screening of protein-protein interactions | |
| US8470523B2 (en) | Method for detecting intracellular interaction between biomolecules | |
| Sakamoto et al. | Construction of ligand assay systems by protein-based semisynthetic biosensors | |
| US20210382054A1 (en) | Methods for screening ubiquitin ligase agonists | |
| Nesakumar et al. | Development of Ligand Assay Systems Using Semisynthetic Biosensors Based on Protein | |
| Yamaura et al. | Construction of Protein-Based Biosensors Using Ligand-Directed Chemistry for Detecting Analyte Binding | |
| Chen | T Luminescence Imaging and Biosensing in Cells and Tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |
|
| EEER | Examination request |
Effective date: 20220912 |